

Di Tanna GL, Bychenkova A, O'Neill F, Wirtz HS, Miller P, Ó Hartaigh B, Globe G

Correspondence to: Gian Luca Di Tanna, Health Economics Senior Manager, Global Health Economics, Amgen (Europe) GmbH Suurstoffi 22, P.O. Box 94, CH-6343 Rotkreuz, Switzerland; Tel: +41 (0)41 369 25 11; Email: gditanna@amgen.com

Online Resource 1. Search strategy

In COCHRANE LIBRARY database we used the following MeSH descriptors (published from 1997 to 2017, in Technology Assessments and Economic Evaluations): '[Heart Failure] explode all trees', 'heart next failure', 'chf or hf', 'cardiomyopath*', '(cardiac next failure) or (cardiac next insufficiency)', '(myocardial next failure) or (myocardial next insufficiency)'.

In MEDLINE and EMBASE (via Ovid) we searched for the following disease terms: 'exp *heart failure/', '((cardiac* or heart* or myocardi*) adj2 (failure* or incompet* or insufficien* or arrest*)).ti,ab.'; we search for the following economic evaluation terms: 'health economics/ or exp economic evaluation/ or cost-benefit analysis/ or cost benefit/ or cost effectiveness analysis/ or cost minimization analysis/ or "costs and cost analysis"/ or quality-adjusted life years/ or value of life/', 'Economics/ or Socioeconomics/ or economic aspect/ or health economics/', '(cost* adj (effective* or utilit* or consequence* or benefit* or minimi*)).tw.', '(economic evaluation* or economic analysis or QALY* or DALY* or quality adjusted or adjusted life year* or disability adjusted life or qald* or qtime* or life year* gained or ICER).ti,ab,kf.'.

In addition, we applied the following exclusion terms: '(comment or editorial or meta-analysis or practice-guideline or review or letter or journal correspondence).pt.', '(book or conference paper or editorial or letter or review).pt.', '(animal* not human*).sh,hw.', '(case stud* or case report*).ti.', '(conference abstract or conference review).pt.'.